Deadly prostate cancer type may be far more common than thought

This article was taken from: http://home.bt.com/news/science-news/deadly-prostate-cancer-type-may-be-far-more-common-than-thought-11364282743120

By BT News

The t-SCNC subtype could account for 17% of treatment-resistant prostate cancers, research has shown

A highly deadly form of aggressive prostate cancer may be far more common than was previously thought, research suggests.

Scientists who studied 160 men whose cancers had spread and were resistant to standard treatment found that 17% had the lethal subtype.

Previously it was thought that the strain accounted for less than 1% of all prostate cancers.

However the same study offered a glimmer of hope for men with the subtype, known as treatment-emergent small cell neuroendocrine prostate cancer (t-SCNC).

“We want to know why prostate cancer becomes resistant, and we believe the emergence of t-SCNC is one important mechanism through which they evolve and evade treatment”.

It found that t-SCNC tumours contained two growth-fuelling proteins that could be targeted by drugs now being tested in clinical trials.

Dr Rahul Aggarwal, one of the US researchers from the University of California at San Francisco (UCSF), said: “We want to know why prostate cancer becomes resistant, and we believe the emergence of t-SCNC is one important mechanism through which they evolve and evade treatment.”

The study found that t-SCNC cancers had mutations that led to the over-production of certain proteins that drove cancer growth.

Among them were two “transcription factors” – molecules that switch on production of other proteins – already being targeted in clinical trials.

Other mutations previously shown to play a role in many “normal” cancers were almost never present in the t-SCNC subtype.

All the men taking part in the study had stopped responding to the advanced second-line hormone treatment drugs abiraterone and enzalutamide.

Biopsy samples showed that 27 out of 160 men had t-SCNC cancers.

They survived 36.6 months on average compared with 44.4 months for patients without the subtype.

Co-author Professor Eric Small, head of haematology and oncology at the UCSF, said: “An understanding of the biology of this important mechanism of resistance is essential to our developing novel therapeutics designed to prevent the development of this lethal prostate cancer subtype, or, once developed, to effectively treat it.”